MGF (5 mg Vial) Dosage Protocol

Plan based on an 8–16 week daily protocol with gradual titration.

• Peptide Vials (MGF, 5 mg each):
  • 8 weeks ≈ 3 vials
  • 12 weeks ≈ 5 vials
  • 16 weeks ≈ 8 vials
• Insulin Syringes (U‑100):
  • Per week: 7 syringes (1/day)
  • 8 weeks: 56 syringes
  • 12 weeks: 84 syringes
  • 16 weeks: 112 syringes
• Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.
  • 8 weeks (3 vials): 9 mL → 1 × 10 mL bottle
  • 12 weeks (5 vials): 15 mL → 2 × 10 mL bottles
  • 16 weeks (8 vials): 24 mL → 3 × 10 mL bottles
• Alcohol Swabs: One for the vial stopper + one for the injection site each day.
  • Per week: 14 swabs (2/day)
  • 8 weeks: 112 swabs → recommend 2 × 100‑count boxes
  • 12 weeks: 168 swabs → recommend 2 × 100‑count boxes
  • 16 weeks: 224 swabs → recommend 3 × 100‑count boxes

MGF 5 mg

View Supplier

U-100 syringes

Bacteriostatic water

View Supplier

Alcohol swabs

PeptideDosages has no affiliation with Pure Lab Peptides and receives no commission from these Pure Lab links. Supplier pages are not scientific evidence or proof of suitability for human use.

• Reconstitute: Add 3.0 mL bacteriostatic water → ~1.67 mg/mL concentration.
• Typical daily range: 100–300 mcg once daily (gradual titration).
• Easy measuring: At 1.67 mg/mL, 1 unit = 0.01 mL ≈ 16.7 mcg on a U‑100 insulin syringe.
• Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); use within ~30 days.

Mechano Growth Factor (MGF) is a splice variant of IGF‑1 (IGF‑1Ec in humans) produced in response to mechanical stress and tissue damage^[1][2]. Research indicates MGF plays a role in muscle repair, satellite cell activation, and bone regeneration^[3][4]. This educational protocol presents a once‑daily subcutaneous approach using a practical dilution for clear insulin‑syringe measurements.

Concise summary of the once‑daily regimen.

• Goal: Support tissue repair and regenerative processes through localized growth factor signaling^[3][4].
• Schedule: Daily subcutaneous injections for 8–12 weeks (extend to 16 weeks if desired).
• Dose Range: 100–300 mcg daily with gradual titration.
• Reconstitution: 3.0 mL per 5 mg vial (~1.67 mg/mL) for accurate unit measurements.
• Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze–thaw.

Suggested daily titration approach.

• Start: 100 mcg daily; increase by ~50 mcg weekly as tolerated.
• Target: 250–300 mcg daily by Weeks 4–8.
• Frequency: Once per day (subcutaneous).
• Cycle Length: 8–12 weeks; optional extension to 16 weeks.
• Timing: Any consistent time; rotate injection sites.

Proper storage preserves peptide quality.

• Lyophilized: Store at −20 °C (−4 °F) or colder for long‑term; refrigerate at 4 °C (39.2 °F) for short‑term.
• Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within approximately 30 days; avoid freeze–thaw cycles.
• Allow vials to reach room temperature before opening to reduce condensation uptake.

Practical considerations for consistency and safety.

• Use new sterile insulin syringes; dispose in a sharps container.
• Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation^[7].
• Inject slowly; wait a few seconds before withdrawing the needle.
• Document daily dose and site rotation to maintain consistency.
• MGF has a short half‑life; PEGylated forms (PEG‑MGF) offer extended duration but follow different protocols^[2].

MGF is generated through alternative splicing of the IGF‑1 gene in response to mechanical loading or tissue injury^[1][2]. The resulting peptide contains a unique C‑terminal E domain that distinguishes it from systemic IGF‑1. Preclinical research demonstrates MGF activates satellite cells (muscle stem cells), promotes osteoblast proliferation, and supports neurogenesis^[3][4][8]. These effects appear to be localized and transient, suggesting MGF acts primarily as a tissue‑specific repair signal rather than a systemic growth factor.

Observations from preclinical literature (no formal human clinical trials have been completed).

• Promotes satellite cell activation and myoblast proliferation in muscle tissue^[1][9].
• Supports bone defect healing and osteoblast activity in animal models^[3].
• May promote neurogenesis and neuroprotection in aging brain tissue^[8].
• Generally well tolerated in preclinical settings; occasional mild injection‑site reactions may occur with subcutaneous administration.
• Long‑term safety data in humans is limited; preclinical models suggest localized rather than systemic effects.

Complementary strategies for best outcomes.

• Pair with resistance training to provide the mechanical stimulus that naturally upregulates MGF expression^[1].
• Ensure adequate protein intake (1.6–2.2 g/kg) to support tissue repair processes.
• Prioritize sleep and recovery; growth factor activity is enhanced during rest periods.
• Manage inflammation through balanced nutrition to optimize the repair environment.

General subcutaneous guidance from clinical best‑practice resources^[10].

• Clean the vial stopper and skin with alcohol; allow to dry.
• Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue^[7][11].
• Do not aspirate for subcutaneous injections; inject slowly and steadily^[7].
• Rotate sites systematically (abdomen, thighs, upper arms) by at least 1–1.5 inches from prior sites to avoid irritation^[11].
• Use 23–25 gauge, 5/8‑inch needles for subcutaneous administration^[7].

We recommend Pure Lab Peptides for high‑purity MGF (5 mg).

Shop at Pure Lab Peptides

This content is for educational purposes only and is not medical advice.

• 1
  
  PLOS ONE (2013)
  — Insulin‑like growth factor I (IGF‑1) Ec/Mechano Growth Factor: splice variant characterization within the growth plate

  View Source
• 2
  
  Journal of Molecular Endocrinology (2003)
  — Expression of IGF‑I splice variants and structural genes in repair of rabbit tendon

  View Source
• 3
  
  International Orthopaedics (2011)
  — Mechano growth factor E peptide promotes osteoblast proliferation and bone‑defect healing in rabbits

  View Source
• 4
  
  Journal of Physiology (2003)
  — Mechano growth factor and other IGF‑I splice variants: expression and possible functions

  View Source
• 7
  
  CDC (Subcut Injection PDF)
  — Vaccine administration: subcutaneous injection technique and site guidance

  View Source
• 8
  
  Molecular Brain (2017)
  — Mechano growth factor promotes neurogenesis in the aging mouse brain

  View Source
• 9
  
  Experimental Cell Research (2008)
  — MGF E‑peptide activates human muscle satellite cells

  View Source
• 10
  
  Subcutaneous Drug Injection Review (PMC)
  — Pharmacologic considerations of the subcutaneous route

  View Source
• 11
  
  Johns Hopkins Arthritis Center
  — How to give a subcutaneous injection (site rotation and technique)

  View Source
• 12
  
  Pure Lab Peptides
  — MGF (5 mg) product page (quality and batch documentation)

  View Source

Explore the available research context, protocol variants or comparisons, and practical guides. When vial-size variants exist, they remain separate because vial strength, concentration, and syringe-unit calculations can differ. Related compounds and blends are comparisons only, not interchangeable.